Other Clinical Trial - Study to Assess the Occurrence of HPA-1a

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06435845` - Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization	Phase 2
Completed	`NCT04067375` - Towards Routine HPA-screening In Pregnancy to Prevent FNAIT
Enrolling by invitation	`NCT04529382` - Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia
Completed	`NCT03561909` - Kinetics of Blood Platelets Transfused to Healthy Subjects	N/A

See also

Status

Clinical Trial

Phase

Not yet recruiting

NCT06435845 - Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Phase 2

Completed

NCT04067375 - Towards Routine HPA-screening In Pregnancy to Prevent FNAIT

Enrolling by invitation

NCT04529382 - Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia

Completed

NCT03561909 - Kinetics of Blood Platelets Transfused to Healthy Subjects

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05345561
Study type	Observational
Source	Rallybio IPA, LLC
Contact	Chief Medical Officer
Phone	(203) 859-3820
Email	clinicaltrials@rallybio.com
Status	Recruiting
Phase
Start date	March 14, 2022
Completion date	June 2027

Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms